Lianya Pharmaceutical (301569.SZ), which is engaged in the development of complex pharmaceutical preparations, plans to be listed on the GEM IPO

According to the Zhitong Finance App, Lianya Pharmaceutical (301569.SZ) issued an initial public offering of shares and a prospectus of intent to list on GEM. The number of shares in this public offering was 13,37395.63 million shares, accounting for 15% of the total share capital after issuance. The initial inquiry date is September 22, 2026, and the subscription date is September 28, 2026. The number of initial strategic placements issued in this offering was 40,1218.68 million shares, accounting for approximately 30.00% of the current offering. Among them, the issuer's senior management and core employees participating in the special asset management plan set up in this strategic placement are expected to be no more than 10.00% of the number of subscriptions, that is, no more than 13.3739.56 million shares, and the subscription amount is no more than 31.3 million yuan; other investors participating in the strategic placement have a total subscription amount of no more than 30 million yuan; the initial follow-up amount of the sponsor's related subsidiaries is approximately 5.00% of the current issuance volume, or 6.686.978 million shares.

The company is a company limited by Lianya Limited as a whole and changed in accordance with law on March 22, 2022. The company is an R&D-driven high-tech enterprise, mainly engaged in R&D, production and sales of complex pharmaceutical preparations. The company's current products include different types of controlled release formulations and two types of high-end generic drugs represented by low-dose pharmaceutical preparations, which are currently mainly used in the fields of hypertension, coronary artery disease, diabetes, schizophrenia, female contraception and health; at the same time, the company also provides CRO and other services to pharmaceutical companies and R&D institutions with leading drug design capabilities and formulation process technology; during the reporting period, the company mainly sold to the US market, and many products had the highest share in the US market.

The company has also been deeply involved in the CRO service field for many years. The level of research and development has been recognized by internationally renowned pharmaceutical companies, and its customers include companies around the world, such as the United States and Italy. New drug formulations that provide CRO services to participate in development have obtained 2 NDA approvals from the FDA, and several new pharmaceutical products that provide CRO services to participate in development are in phase III clinical phase.

During the reporting period, the company's revenue was 700.43 million yuan, 866.22 million yuan and 895.47 million yuan respectively, increasing its ability to operate continuously. In addition, the company has a rich pipeline of products under development. As of March 31, 2026, the company has 39 generic drug research projects and 2 improved new drug research projects, many of which have potential for initial simulation. The gradient product pipeline provides sufficient guarantees for the company's future profits.

After deducting the issuance fee, all of the funds raised will be used for the following projects: industrialization base projects, drug development projects, and supplementary working capital. It is planned to use the amount of capital raised this time: 950 million yuan.